Our six research programmes are contained within three Clusters:
1. Immune tolerance
3. Inherited disease
Our goal is to better
regulation at a cellular
and molecular level, apply this knowledge
to clinical conditions,
and develop strategies to correct defective
regulation with new
Bioengineered tissue transplantation
We study the nature of immune responses in liver and renal transplant patients. We also study immune stimulation by synthetic biomaterials, engineered tissues and therapeutic genes, with the aim to develop tolerance-inducing interventions to prevent immune attack and rejection.
Immunotherapy of cancer
We research the mechanisms of cancer immunity and cancer-induced tolerance in patients and in experimental models. Genetic engineering of immune cells provides an opportunity to produce cancer-specific T cells that are resistant to cancer-induced immune suppression.
Chronic infection with hepatitis B virus, cytomegalovirus and HIV is associated with defective immunity. Uncovering the mechanisms of immune deviation provides a platform for developing immune enhancing therapies to achieve viral immunity in chronic infection.
We focus on improving early diagnosis and therapy of primary immunodeficiency by joining detailed genomic analysis, mechanistic immune function studies and comprehensive clinical data.
Gene therapy of inherited defects
We delivered the first successful gene therapy for haemophilia B using AAV based gene delivery. This work has provided a strong basis to expand this form of gene therapy to other conditions, including haemophilia A and lysosomal storage disease.
Page last modified on 24 jun 15 11:12